Work with LifeSpan to design a custom immunohistochemistry to address your specific biological question. Outsource the entire localization process without having to
worry about finding and characterizing target specific antibodies, sourcing and validating difficult-to-find tissues, and having the ability to interpret the resulting
immunostaining in relation to complex human pathologies.
TCR Screening Services
Test your therapeutic antibodies in immunohistochemistry against a broad panel of normal frozen human tissue types in order to determine potential unintended binding.
Our non-GLP TCR services are designed on the FDA recommendation outlined in their "Points to Consider in the Manufacture and Testing of Monoclonal Antibody Products for Human Use".
Description: Angiotensin II, as part of the renin-angiotensin-aldosterone system, facilitates a sympathetic nervous system response mediated by the angiotensin II type 1 (AT1) receptor, causing vasoconstriction and subsequent increase in blood pressure. It potentiates noradrenaline release from sympathetic nerve terminals at the presynaptic level as well as amplifies the alpha -adrenoceptor-mediated vasoconstrictor response to endogenous noradrenaline. Angiotensin II receptor blockers (ARBs) are a major class of therapeutics designed to lower blood pressure and to provide cardiovascular protection. Eprosartan (mesylate) is a competitive AT1 receptor antagonist with IC50 values ranging from 1.4 â€“ 3.9 nM and an elimination half-life of five to seven hours. Eprosartan is structurally distinct from other noncompetitive ARBs in that it does not contain a biphenyl, tetrazole moiety and blocks angiotensin II receptors on both sympathetic nerve terminals and blood vessels.
Eprosartan (mesylate) is supplied as a crystalline solid. A stock solution may be made by dissolving the eprosartan (mesylate) in the solvent of choice. Eprosartan (mesylate) is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide (DMF), which should be purged with an inert gas. The solubility of eprosartan (mesylate) in ethanol is approximately 1 mg/ml and approximately 30 mg/ml in DMSO and DMF. Eprosartan (mesylate) is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, eprosartan (mesylate) should first be dissolved in DMSO and then diluted with the aqueous buffer of choice. Eprosartan (mesylate) has a solubility of approximately 0.5 mg/ml in a 1:1 solution of DMSO:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.
Munger, M.A. Use of angiotensin receptor blockers in cardiovascular protection: Current evidence and future directions. PT 36(1), 22-40 (2011).
Blankestijn, P.J. and Rupp, H. Clinical profile of eprosartan: A different angiotensin II receptor blocker. Cardiovasc. Hematol. Agents Med. Chem. 6(4), 253-257 (2008).
Burnier, M. Angiotensin II type 1 receptor blockers. Circulation 103, 904-912 (2001).